Market Place
Sourcing Support
Scisparc, Clearmind Medicine Partner For Depression Therapy
16 Mar 2026 //
GLOBENEWSWIRE
Clearmind Medicine Files Hong Kong Patent For Depression Therapy
13 Mar 2026 //
GLOBENEWSWIRE
Polyrizon Inks Deal For Intranasal Neuroplastogen Formulation
06 Feb 2026 //
GLOBENEWSWIRE
Neurothera, Clearmind Secure Patent for Novel Depression Therapy
20 Nov 2025 //
GLOBENEWSWIRE
Scisparc & Clearmind Collaborate On US Patent For Binge Behavior
20 Oct 2025 //
GLOBENEWSWIRE
Clearmind Medicine Convenes First Scientific Advisory Board
25 Sep 2025 //
GLOBENEWSWIRE
Clearmind Gets IRB OK for Ph 1/2a Alcohol Use Disorder Trial
05 Aug 2025 //
GLOBENEWSWIRE
SciSparc-Clearmind Patent for Weight Loss, Fatty Liver Therapy
30 Jul 2025 //
GLOBENEWSWIRE
Clearmind Opens Israeli Site for CMND-100 Alcohol Trial
23 Jul 2025 //
GLOBENEWSWIRE
Clearmind Gets IRB Approval for Alcohol Disorder Trial in Israel
03 Jul 2025 //
GLOBENEWSWIRE
Clearmind Medicine Expands Global Alcohol Use Disorder Trial
27 Jun 2025 //
GLOBENEWSWIRE
Clearmind Adds Israeli Site to Alcohol Use Disorder Trial
23 Jun 2025 //
GLOBENEWSWIRE
Clearmind Medicine Hires Firm to Advance Psychedelic Therapeutics
12 Jun 2025 //
GLOBENEWSWIRE
Clearmind Starts Ph I/IIa Trial for Alcohol Use Disorder Drug
05 Jun 2025 //
GLOBENEWSWIRE
SciSparc-Clearmind Win EU Patent for Cocaine Therapy
12 May 2025 //
GLOBENEWSWIRE
SciSparc-Clearmind File Patent for Eating Disorder Therapy
25 Apr 2025 //
GLOBENEWSWIRE
Clearmind To Evaluate Intranasal Psychedelic Drug Combo
19 Mar 2025 //
GLOBENEWSWIRE
Clearmind: 1st Human Trial with CMND-100 in Alcohol Use Disorder
18 Mar 2025 //
GLOBENEWSWIRE
Clearmind Patents Psychedelic Combo For Cocaine Addiction In Korea
10 Mar 2025 //
GLOBENEWSWIRE
SciSparc, Clearmind Patent Psychedelic Combo For Cocaine Addiction
10 Mar 2025 //
GLOBENEWSWIRE
Clearmind Publishes Patent for Binge Behavior Psychedelic Treatment
04 Feb 2025 //
GLOBENEWSWIRE
SciSparc-Clearmind File European Patent For Psychedelic Treatment
06 Jan 2025 //
GLOBENEWSWIRE
SciSparc-Clearmind Patent For Ibogaine Combination Therapy
16 Sep 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Ketamine-Based Combination Patent Application Published
29 Aug 2024 //
GLOBENEWSWIRE
Clearmind Medicine To Source Makers For Alcohol Substitute Beverage
19 Jul 2024 //
GLOBENEWSWIRE
Clearmind Medicine Files US Patent For Metabolic Syndrome Treatment
16 Jul 2024 //
GLOBENEWSWIRE
Clearmind Medicine Gets FDA IND Approval For Alcoholism Treatment Trial
16 Jul 2024 //
GLOBENEWSWIRE
Clearmind Medicine To Present At Psychedelic Medicine - Israel 2024 Conference
12 Jul 2024 //
GLOBENEWSWIRE
Clearmind Medicine Granted Hong Kong Patent For Binge Behaviors Treatment
28 Jun 2024 //
GLOBENEWSWIRE
Clearmind Medicine Secures Global Rights To Psychedelic Compounds For PTSD
20 Jun 2024 //
GLOBENEWSWIRE
Clearmind Advances Psychedelic Synthetic Alcohol Beverage Product
10 May 2024 //
GLOBENEWSWIRE
Clearmind Secures Rights To Psychedelic Compounds For PTSD
07 May 2024 //
GLOBENEWSWIRE
Clearmind Applies to Cease Being a Reporting Issuer in Canada
30 Apr 2024 //
GLOBENEWSWIRE
Clearmind Licenses Generation 3.0 Psychedelic Compounds
17 Apr 2024 //
GLOBENEWSWIRE
Clearmind Medicine Files Patent for Psychedelic Eating Disorder Treatment
10 Apr 2024 //
GLOBENEWSWIRE
Clearmind Medicine CEO Issues Letter to Shareholders
09 Apr 2024 //
GLOBENEWSWIRE
SciSparc- Clearmind Collab Evolves with New International Patent Application
27 Mar 2024 //
GLOBENEWSWIRE
Clearmind Announces International Patent Application for Treating Depression
27 Mar 2024 //
GLOBENEWSWIRE
Breakthrough in Wellness: Clearmind Medicine`s Psychedelic Treatment Granted
19 Mar 2024 //
GLOBENEWSWIRE
Clearmind Medicine Received Approval for Voluntary Delisting of Common Shares
13 Mar 2024 //
GLOBENEWSWIRE
Clearmind Medicine Obtains Clearance for its Alcoholism Clinical Trial
13 Mar 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Partnership Yields Three International Patent Applications
27 Feb 2024 //
GLOBENEWSWIRE
Clearmind Medicine Receives Approval to Commence Ph I/IIa Trial of CMND-100
23 Feb 2024 //
GLOBENEWSWIRE
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio
20 Feb 2024 //
GLOBENEWSWIRE
Clearmind Submits Patent Applications for Psychedelic-Based Compounds
20 Feb 2024 //
GLOBENEWSWIRE
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment
05 Feb 2024 //
GLOBENEWSWIRE
Clearmind Medicine Announces Agreement with Leading Israeli Research Center
01 Feb 2024 //
GLOBENEWSWIRE
Clearmind Medicine Closes US$2.4 Million Registered Direct and Private Placement
16 Jan 2024 //
GLOBENEWSWIRE
Clearmind Medicine Announces Pricing of $2.4 Million Registered Direct Placement
11 Jan 2024 //
GLOBENEWSWIRE
Clearmind Medicine Completed Type A Meeting with the FDA
10 Jan 2024 //
GLOBENEWSWIRE
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023
04 Jan 2024 //
GLOBENEWSWIRE
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
05 Dec 2023 //
GLOBENEWSWIRE
Clearmind`s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
01 Dec 2023 //
GLOBENEWSWIRE
Clearmind Announces Results from Weight Loss and Metabolic Disorder Program
28 Nov 2023 //
GLOBENEWSWIRE
Clearmind to Participate in Traditional vs. Novel Psychedelics Virtual Event
27 Nov 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces 1-for-30 Reverse Share Split
21 Nov 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice
17 Nov 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces Shareholders Meeting Results
15 Nov 2023 //
GLOBENEWSWIRE
Clearmind Medicine to Pioneer Psychedelic Trials for Alcohol Use Disorder
09 Nov 2023 //
GLOBENEWSWIRE
Clearmind to Present at the 8th Annual Dawson James Conference on October 12th
05 Oct 2023 //
GLOBENEWSWIRE
